CDKN2A and cancer: For the individual TSGs TP53, SPEN, CDKN2A, ATRX, RBM10, and AMER1 it was possible to show a significant increase in VAFs in CNA loss states, compared to the set of random genes as a baseline, at FDR ≤ 5% (12 genes significant in total across all cognate cancer types at FDR ≤ 25%, see full list in Supplementary Fig. S8a).